Institutional
CAXTON CORP
CIK 0001388551
$4.0M
Reported AUM
7
Positions
Q1 2026
Period
2026-05-14
Filed
The Brief · CAXTON CORP · Q1 2026
AI · grounded in 13F
CAXTON CORP closed its position in SYRE, reducing its exposure by $292,194. The fund also exited positions in BRD1EUR and CMPX, with losses of $210,058 and $158,386 respectively. To offset these exits, the fund established a new position in ALXO worth $41,996 and increased its holdings in GLD by 9.463%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GLD | SPDR GOLD TR | $371.08 | 0.46% | 19.49% | 117.67% | $3.3M | 81.50% | — | HELD |
| 2 | BRK/B | BERKSHIRE HATHAWAY INC DEL | — | — | — | — | $348K | 8.66% | — | HELD |
| 3 | KYTX | KYVERNA THERAPEUTICS INC | $7.07 | -5.61% | 117.73% | -69.85% | $162K | 4.03% | — | HELD |
| 4 | LXEO | LEXEO THERAPEUTICS INC | $4.31 | -1.82% | -4.77% | -67.29% | $80K | 1.99% | — | HELD |
| 5 | XFOR | X4 PHARMACEUTICALS INC | $4.00 | 1.78% | 145.63% | -97.45% | $64K | 1.60% | — | HELD |
| 6 | IKT | INHIBIKASE THERAPEUTICS INC | $2.21 | -4.33% | 45.39% | -84.46% | $48K | 1.19% | — | HELD |
| 7 | ALXO | ALX ONCOLOGY HLDGS INC | $1.95 | -2.26% | 275.48% | -97.22% | $42K | 1.04% | — | HELD |
Source: SEC EDGAR · accession 0000919574-26-003017. 13F discloses long positions only — shorts, foreign equities, and options are excluded.